SEARCH

SEARCH BY CITATION

References

  • 1
    Jhaveri R, Grant W, Kauf TL, McHutchison J. The burden of hepatitis C virus infection in children: estimated direct medical costs over a ten-year period. J Pediatr 2006; 148: 353-358.
  • 2
    European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 45-51.
  • 3
    Murray KF, Finn LS, Taylor SL, Seidel KD, Larson AM. Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2005; 41: 634-638.
  • 4
    González-Peralta RP, Langham MR, Andres JM, et al. Hepatocellular carcinoma in two young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48: 630-635.
  • 5
    Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-458.
  • 6
    Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. HEPATOLOGY 2005; 42: 1010-1018.
  • 7
    Wirth S, Lang T, Gehring S, Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. HEPATOLOGY 2002; 36: 1280-1284.
  • 8
    Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. HEPATOLOGY 2007; 45: 806-816.
  • 9
    Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-2539.
  • 10
    Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. HEPATOLOGY 2005; 41: 790-800.
  • 11
    Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847-854.
  • 12
    Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13: 507-511.
  • 13
    Schäfer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C — a critical review. Int J Methods Psychiatr Res. 2007; 16: 186-201.
  • 14
    Forton DM, Allsop JM, Cox IJ, Hamilton G, Wesnes K, Thomas HC, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS 2005; 19( Suppl 3): S53-S63.
  • 15
    Lieb K, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Janssen G, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006; 21: 204-210.
  • 16
    Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19: S174-S178.
  • 17
    Leutscher PD, Laggin M, Buhl MR, Pedersen C, Norkrans G, Langeland N. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. HEPATOLOGY 2010; 52: 430-435.
  • 18
    Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. HEPATOLOGY 2008; 23: 226-230.
  • 19
    Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341-347.
  • 20
    Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, Vajro P, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997; 16: 984-990.
  • 21
    Murray KF, Rodrigue JR, González-Peralta RP, Shepherd J, Barton BA, Robuck PR, et al. Design of the PEDS-C Trial: pegylated interferon +/− ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661-673.
  • 22
    Landgraf JM, Abetz L, Ware JE. The CHQ User's Manual. Boston: The Health Institute, New England Medical Center; 1996.
  • 23
    Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms & profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2001.
  • 24
    Kovacs M. Children's Depression Inventory Manual. North Tonawanda, NY: Multi-Health Systems; 1992.
  • 25
    Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior Rating Inventory of Executive Function. Odessa, FL: Psychological Assessment Resources; 2000.
  • 26
    Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. HEPATOLOGY 2002; 35: 704-708.
  • 27
    Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-681.
  • 28
    Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, et al. Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004; 11: 157-165.
  • 29
    Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-349.